Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor

Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have been reported with the use of first-generation BTK...

Full description

Bibliographic Details
Main Authors: Omar Alkharabsheh, Alhareth Alsayed, Diana M. Morlote, Amitkumar Mehta
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Current Oncology
Subjects:
CLL
Online Access:https://www.mdpi.com/1718-7729/28/1/81
Description
Summary:Bruton tyrosine kinase (BTK) inhibitors have become an important therapy for untreated and previously treated patients with chronic lymphocytic leukemia (CLL). Despite improved outcomes, rare adverse events, such as invasive fungal infections, have been reported with the use of first-generation BTK inhibitors. Invasive fungal infections carry a high morbidity and mortality risk. There have been several case reports describing the association between aspergillosis and ibrutinib treatment, but none with acalabrutinib, to our knowledge. In this case report, we describe a patient with CLL who developed an intracranial <i>Aspergillus fumigatus</i> infection while receiving acalabrutinib.
ISSN:1198-0052
1718-7729